Cargando…
Neuroprotective Epigenetic Changes Induced by Maternal Treatment with an Inhibitor of Soluble Epoxide Hydrolase Prevents Early Alzheimer′s Disease Neurodegeneration
Modulation of Alzheimer′s disease (AD) risk begins early in life. During embryo development and postnatal maturation, the brain receives maternal physiological influences and establishes epigenetic patterns that build its level of resilience to late-life diseases. The soluble epoxide hydrolase inhib...
Autores principales: | Bartra, Clara, Irisarri, Alba, Villoslada, Ainhoa, Corpas, Rubén, Aguirre, Samuel, García-Lara, Elisa, Suñol, Cristina, Pallàs, Mercè, Griñán-Ferré, Christian, Sanfeliu, Coral |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740580/ https://www.ncbi.nlm.nih.gov/pubmed/36499477 http://dx.doi.org/10.3390/ijms232315151 |
Ejemplares similares
-
Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson’s Disease: A New Therapeutic Strategy
por: Pallàs, Mercè, et al.
Publicado: (2020) -
Understanding Epigenetics in the Neurodegeneration of Alzheimer’s Disease: SAMP8 Mouse Model
por: Griñán-Ferré, Christian, et al.
Publicado: (2018) -
From the Design
to the In Vivo Evaluation
of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors
for the Treatment of Acute Pancreatitis
por: Codony, Sandra, et al.
Publicado: (2021) -
Discovery and In
Vivo Proof of Concept of a Highly
Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase
for the Treatment of Alzheimer’s Disease
por: Codony, Sandra, et al.
Publicado: (2022) -
Synthesis, In Vitro
Profiling, and In Vivo Evaluation
of Benzohomoadamantane-Based Ureas for Visceral Pain: A New Indication
for Soluble Epoxide Hydrolase Inhibitors
por: Codony, Sandra, et al.
Publicado: (2022)